Ipamorelin is not FDA approved and is not on the list of substances US pharmacies may compound. On 29 October 2024 an FDA advisory committee voted against listing it, 0 for, 12 against and 1 abstention, and the FDA keeps it in Category 2 for outsourcing facilities. It was not part of the July 2026 peptide review.

The short version. Ipamorelin is not FDA approved and is not on the 503A Bulks List. FDA staff recommended against listing it, and on 29 October 2024 the advisory committee agreed, 0 to 12 with one abstention. Outsourcing facilities face it in Category 2. It was not part of the 2026 peptide review, and every human trial gave it into a vein.
Ipamorelin is a chain of five amino acids that binds the ghrelin receptor and makes the pituitary gland release growth hormone. Raun and colleagues at Novo Nordisk described it in 1998 in the European Journal of Endocrinology as the first selective growth hormone secretagogue: in pigs it released growth hormone without raising ACTH or cortisol, unlike the older GHRP-6 and GHRP-2. The FDA briefing prepared for the October 2024 Pharmacy Compounding Advisory Committee notes that the peptide contains unnatural amino acids, which make it harder to characterise, and that suppliers sell both a free base and an acetate salt. The two nominators, Wells Pharmacy Network and LDT Health Solutions, did not make clear which one they meant, so the FDA evaluated both.
The FDA briefing traces ipamorelin's use well beyond the clinic. Outsourcing facility reports show compounding with ipamorelin from 2017 to 2020, and internet searches found compounders preparing it as injections, nasal sprays and oral products. The FDA records that it is marketed for weight loss, anti-ageing, inflammatory conditions, sleep and bodybuilding, increasingly by medical spas and wellness clinics. A June 2026 review in Frontiers in Endocrinology by Dominikowski and colleagues groups ipamorelin with GHRP-2, GHRP-6 and hexarelin among the growth hormone secretagogues sold as research compounds for self-administration, and stresses that none has regulatory approval for physique or performance uses and that product composition, dose and stacking in unregulated supply chains are uncertain.

In plain EnglishIpamorelin is a small lab-made peptide that tells the pituitary to release growth hormone. A drug company tested it in hospitals for bowel recovery after surgery. Today it is sold online for muscle, fat loss and ageing. In the US it is not an approved drug.
Ipamorelin's legal position rests on four dated facts, and all four point the same way. First, the FDA briefing states that neither form is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. Second, ipamorelin is not on the 503A Bulks List, and it does not appear in any interim category of the FDA nominations list updated 14 May 2026; the Federal Register API returned no 2025 or 2026 document naming ipamorelin when we checked on 20 November 2026. Third, the FDA safety-risk page, current as of 22 April 2026, keeps ipamorelin acetate in 503B Category 2, the group that may present significant safety risks, since 29 September 2023. Fourth, the committee voted against it.
| Question | What the record says | Source |
|---|---|---|
| FDA approved product? | None. Not a component of any approved drug | FDA briefing, PCAC October 2024 |
| On the 503A Bulks List? | No | No proposed or final rule |
| 503B status | Category 2, significant safety risks, since 29 Sep 2023 | FDA safety-risk page, 22 Apr 2026 |
| FDA staff view | Against listing either form | FDA briefing memo, 19 Aug 2024 |
| Advisory committee | Against: 0 for, 12 against, 1 abstention | FDA minutes, 29 Oct 2024 |
| July 2026 review and HHS draft policy | Not included in either | Federal Register API, 20 Nov 2026 |
The 2024 vote is the fact most pages ranking for ipamorelin leave out. On 29 October 2024 the committee first agreed, 12 to 1, to vote on the free base and the acetate as a group, then voted 0 in favour, 12 against and 1 abstention on each. According to the FDA minutes, members who voted no cited a lack of information supporting safety and efficacy for growth hormone deficiency and post-operative ileus, and one member said that how often a drug is prescribed does not show it is safe and effective. The abstaining member pointed to confusion between data on the two forms. A committee vote is advice, not a rule, but the advice was unanimous among those who voted.

In plain EnglishThe FDA asked its outside experts in 2024 whether pharmacies should be allowed to make ipamorelin. Twelve said no and one did not vote. Nothing since has changed that, and ipamorelin was not part of the 2026 peptide decisions that made headlines.
Ipamorelin is sold as an injection under the skin. The FDA found no safety data for that route, and its committee voted 0 to 12 against letting pharmacies compound it.
The 2026 news on peptides does not cover ipamorelin. The committee that met on 23 and 24 July 2026 reviewed seven peptides, BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax and emideltide, and the HHS draft enforcement policy published on 30 October 2026, FR Doc. 2026-22192, names six. Ipamorelin is not in either group, because its own review had already ended in October 2024. The Ozemback peptide legal status tracker shows the legal position of 28 compounds with the date of each fact, and the approved, recommended or neither quiz tests how well the headlines held up. For the July meeting, see our analysis of the vote.
The FDA's conclusion: the trials did not show a significant benefit for post-operative ileus, there are no effectiveness data for growth hormone deficiency, and none for the injection under the skin that was nominated.

The only published efficacy trial is Beck and colleagues, 2014, in the International Journal of Colorectal Disease. It was a phase 2, double-blind, placebo-controlled study run with Helsinn (NCT00672074): 117 adults having small or large bowel resection were enrolled and 114 were analysed, 56 on intravenous ipamorelin twice daily and 58 on placebo, for up to seven days. The median time to a first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a gap of 7.3 hours that was not statistically significant (p = 0.15), and secondary endpoints showed no difference either. A second Helsinn phase 2 trial, NCT01280344, enrolled 320 patients and was completed in May 2014, but ClinicalTrials.gov shows no posted results as of 20 November 2026.
The growth hormone deficiency claim rests on even less. The nominators cited Gobburu and colleagues, 1999, a randomised, placebo-controlled dose-escalation study in 48 healthy men that measured how ipamorelin moves through the body and how much growth hormone it releases. That study found a half-life of about two hours and a single pulse of growth hormone peaking at around 40 minutes. The FDA notes it did not diagnose or treat anyone with growth hormone deficiency, and the agency found no other publication that did. FDA approved growth hormone products exist for that condition, which the briefing lists.
In plain EnglishA drug company tested ipamorelin on patients recovering from bowel surgery. They ate a few hours sooner on average, but not by enough to rule out chance, and a bigger trial never published its results. Nobody has shown it treats growth hormone deficiency.
The FDA's safety concerns start with the trial itself. In the Beck study, as summarised in the FDA briefing, low potassium (12.5 percent versus 3.4), insomnia (10.7 versus 5.2) and high blood sugar at discharge (14.3 versus 8.6) were more frequent on ipamorelin than on placebo. Two patients on ipamorelin, both operated on for colon cancer, died after anastomotic leaks, with sepsis among the causes of death; the FDA states it is unclear whether the deaths were related to ipamorelin, but says their occurrence, alongside the potassium and glucose findings, raises safety concerns. The FDA's FAERS search through 30 September 2023 found two non-serious reports. The agency also flagged immunogenicity and aggregation risk for an injected peptide with unnatural amino acids.
There is no FDA approved dose of ipamorelin, because there is no FDA approved product.
Every ipamorelin dose figure online comes from somewhere other than a US label. The Helsinn trials and the 1999 volunteer study gave the peptide into a vein, dosed by body weight, in hospital or research settings, which says nothing about the subcutaneous injections, nasal sprays and oral products sold today. The FDA briefing says it has not identified safety information for ipamorelin by other injectable routes, so the agency lacks the data to know whether it would cause harm given that way. The briefing also warns that it has no data to rule out the risks seen with approved products that raise growth hormone. We report this because it is the record, and we do not publish a recommended dose, cycle, stack or protocol for ipamorelin or any other compound.

Check whether the page mentions the October 2024 vote at all; many ipamorelin pages describe the 2026 peptide wave as if it covered every growth hormone peptide, and this one was voted down two years earlier. Check whether the "selective" and "few side effects" claims cite the 1998 pig study or a human trial, and whether that trial gave ipamorelin into a vein, as all of them did, or the way the page is selling it. Check who pays the author: nearly every site ranking for ipamorelin benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 20 November 2026, so you can tell when it stops being current. Related files: Sermorelin and Tesamorelin, the growth hormone releasing peptides with an FDA approval history.
Ipamorelin is not an FDA approved drug and is not on the 503A Bulks List of substances pharmacies may compound. An FDA advisory committee voted against listing it on 29 October 2024, 0 for, 12 against and 1 abstention, and the FDA lists ipamorelin acetate in Category 2 for outsourcing facilities. Whether a specific seller is acting lawfully is a question for a lawyer.
No. The FDA briefing for the October 2024 committee states that neither ipamorelin free base nor ipamorelin acetate is a component of an FDA approved drug, and neither has a United States Pharmacopeia monograph. Its only efficacy trials, two Helsinn phase 2 studies in bowel surgery, gave it into a vein.
No. The FDA committee of 23 and 24 July 2026 reviewed seven peptides, and the HHS draft policy of 30 October 2026 covers six. Ipamorelin is in neither. Its committee vote happened in October 2024, and it went against. The peptide legal status tracker shows where each compound stands.
The record does not show a clinical benefit. In the only published efficacy trial, 114 patients after bowel surgery, the median time to a first tolerated meal was 25.3 hours on ipamorelin and 32.6 on placebo, a difference that was not statistically significant. The FDA found no effectiveness data for growth hormone deficiency.
There is no FDA approved dose, because there is no FDA approved product. The trials gave ipamorelin into a vein, dosed by body weight, in hospital, which tells you nothing about the injections sold online. We do not publish a dose, cycle or protocol for this or any compound.
In the 2014 surgical trial, low potassium, insomnia and high blood sugar at discharge were more frequent on ipamorelin than on placebo, and two patients on ipamorelin died after complications; the FDA says it is unclear whether the deaths were related to the drug. The FDA found no safety data for injection under the skin.
No. Ipamorelin acts on the ghrelin receptor, while CJC-1295 is a growth hormone releasing hormone analogue, and the two are often sold together. Neither is FDA approved, and the FDA safety-risk page lists concerns about each. The tracker carries both.
Whatever you decide, your own numbers are the one part of this that is not contested. A baseline panel costs less than a month of most things sold in this category and it is yours to keep.
Ozemback is not a provider and takes no part in any clinical decision. The link above is an affiliate link: if you buy a panel through it we receive a commission at no additional cost to you. We are paid for the referral, never for the result, and it does not change what we publish.